Companies in #CAR-T

AbelZeta Pharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapies and antibody-based immuno-oncology treatments, with operations in the US and China.

Cellares is the first Integrated Development and Manufacturing Organization (IDMO), using an Industry 4.0 approach to mass-manufacture cell therapies. Its Cell Shuttle platform automates and scales the production of CAR-T and other cell therapies, serving clinical and commercial-stage developers.

Fate Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf NK and T-cell cancer immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes FT596 (CD19 CAR-NK), FT819 (CD19 CAR-T), and FT522 (CD19 + IL-15 CAR-NK) in hematologic malignancies and autoimmune disease.

New cell therapy licensing company founded by Ying Huang (former Legend Biotech CMO). Focused on licensing Asian cell therapy assets into Western markets with a $250M target raise.